Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of glomerular mesangial cell proliferation. [GOC:mtg_kidney_jan10]
The regulation of glomerular mesangial cell proliferation is a complex process involving a delicate balance of stimulatory and inhibitory signals that govern cell growth, differentiation, and survival. This intricate interplay of factors ensures the proper development and function of the glomerulus, the filtering unit of the kidney.
**Growth Factors and Cytokines:**
* **Platelet-derived growth factor (PDGF):** A potent mitogen for mesangial cells, PDGF stimulates cell proliferation and extracellular matrix production. Its expression is elevated in various glomerular diseases, contributing to mesangial cell hyperplasia and glomerular sclerosis.
* **Transforming growth factor-beta (TGF-beta):** While initially thought to inhibit proliferation, TGF-beta has a more complex role in mesangial cells. It can induce cell growth in certain contexts but also promotes extracellular matrix accumulation, leading to glomerulosclerosis.
* **Interleukin-1 (IL-1):** This pro-inflammatory cytokine induces mesangial cell proliferation, collagen synthesis, and the release of pro-inflammatory mediators, further exacerbating glomerular injury.
* **Insulin-like growth factor (IGF):** IGF-1 promotes mesangial cell proliferation and has been implicated in the pathogenesis of diabetic nephropathy.
**Cellular Signaling Pathways:**
* **MAPK Pathway:** This signaling cascade, activated by growth factors like PDGF and TGF-beta, plays a crucial role in regulating cell proliferation, differentiation, and survival.
* **PI3K/Akt Pathway:** This pathway, activated by various growth factors and cytokines, promotes cell survival and proliferation.
* **JAK/STAT Pathway:** This pathway, activated by cytokines like IL-1, mediates inflammatory responses and influences mesangial cell proliferation.
**Extracellular Matrix Components:**
* **Collagen:** Mesangial cells produce various collagen types, including type IV, which contributes to the glomerular basement membrane. Increased collagen deposition is a hallmark of glomerulosclerosis.
* **Fibronectin:** This extracellular matrix protein is involved in cell adhesion and migration and is upregulated in mesangial cells during glomerular injury.
**Other Factors:**
* **Angiotensin II:** This vasoconstrictor peptide promotes mesangial cell proliferation and extracellular matrix production, contributing to glomerular hypertrophy and sclerosis.
* **Reactive oxygen species (ROS):** Oxidative stress induces mesangial cell proliferation and contributes to glomerular damage in various kidney diseases.
**Dysregulation and Disease:**
Disruptions in the delicate balance of these regulatory factors can lead to uncontrolled mesangial cell proliferation, resulting in glomerular hypertrophy, sclerosis, and ultimately, kidney failure. This dysregulation is a hallmark of various glomerular diseases, including diabetic nephropathy, lupus nephritis, and IgA nephropathy.
**Therapeutic Implications:**
Understanding the intricate mechanisms regulating mesangial cell proliferation is crucial for developing targeted therapies to prevent or treat glomerular diseases. Strategies aimed at modulating the activity of growth factors, cytokines, and signaling pathways hold promise for preventing excessive mesangial cell proliferation and preserving kidney function.'
"
Protein | Definition | Taxonomy |
---|---|---|
Platelet-derived growth factor subunit A | A platelet-derived growth factor subunit A that is encoded in the genome of human. [PRO:DNx, UniProtKB:P04085] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
tak-632 | TAK-632 : A member of the class of benzothiazoles that is 1,3-benzothiazole substituted by (cyclopropanecarbonyl)amino, 4-fluoro-3-{2-[3-(trifluoromethyl)phenyl]acetamido}phenoxy, and cyano groups at positions 2, 6 and 7, respectively. It is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAF(V600E), BRAF(WT), respectively. | (trifluoromethyl)benzenes; aromatic ether; benzothiazoles; cyclopropylcarboxamide; monofluorobenzenes; nitrile; secondary carboxamide | antineoplastic agent; apoptosis inducer; B-Raf inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; necroptosis inhibitor |